Current guidelines in Europe and the USA recommend that all mCRC patients receive Kirsten rat sarcoma (KRAS) testing prior to treatment with EGFR inhibitors since KRAS mutation status–wild type (WT) or mutant (MT)–predicts the response to anti-EFGR therapies [15, 16]. The gene discussed is KRAS; the disease is sarcoma.